4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)benzamide | 1248589-20-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)benzamide
• 英文别名: 4-[4-(4-Chlorophenyl)pyrazol-1-yl]benzamide；4-[4-(4-chlorophenyl)pyrazol-1-yl]benzamide
• CAS: 1248589-20-9
• 化学式: C₁₆H₁₂ClN₃O
• 分子量: 297.744
• InChiKey: ISMPQCOHFGGZLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-(4-氯苯基)丙二醛 、 4-氨基甲酰苯硼酸 在 偶氮二甲酸二叔丁酯 、 copper(II) acetate monohydrate 、 盐酸 作用下， 以 甲醇 、 1,4-二氧六环 为溶剂， 反应 1.0h， 以40%的产率得到4-(4-(4-chlorophenyl)-1H-pyrazol-1-yl)benzamide
  参考文献：
  名称：

  One-pot copper-catalyzed synthesis of N-functionalized pyrazoles from boronic acids

  摘要：

  A straight-forward route to prepare a diverse set of N-aryl pyrazoles via a one-pot copper-catalyzed boronic acid coupling and cyclization protocol is presented. A variety of aryl and heteroaryl N-functionalized pyrazoles not easily accessible by other means were formed in good yield from readily available boronic acid precursors in an operationally simple procedure. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2010.07.077

文献信息

• Discovery of an <i>in Vivo</i> Tool to Establish Proof-of-Concept for MAP4K4-Based Antidiabetic Treatment
  作者：Mark Ammirati、Scott W. Bagley、Samit K. Bhattacharya、Leonard Buckbinder、Anthony A. Carlo、Rebecca Conrad、Christian Cortes、Robert L. Dow、Matthew S. Dowling、Ayman El-Kattan、Kristen Ford、Cristiano R. W. Guimarães、David Hepworth、Wenhua Jiao、Jennifer LaPerle、Shenping Liu、Allyn Londregan、Paula M. Loria、Alan M. Mathiowetz、Michael Munchhof、Suvi T. M. Orr、Donna N. Petersen、David A. Price、Athanasia Skoura、Aaron C. Smith、Jian Wang

  DOI：10.1021/acsmedchemlett.5b00215

  日期：2015.11.12

  Recent studies in adipose tissue, pancreas, muscle, and macrophages suggest that MAP4K4, a serine/threonine protein kinase may be a viable target for antidiabetic drugs. As part of the evaluation of MAP4K4 as a novel antidiabetic target, a tool compound, 16 (PF-6260933) and a lead 17 possessing excellent kinome selectivity and suitable properties were delivered to establish proof of concept in vivo. The medicinal chemistry effort that led to the discovery of these lead compounds is described herein together with in vivo pharmacokinetic properties and activity in a model of insulin resistance.